DRI Healthcare Trust is scheduled to report results for the quarter ended September 30, 2026, after the market closes on November 4. Analysts expect earnings per share (EPS) of C$0.55 and revenue of about $45.3 million. The company beat estimates in two of its last four comparable quarters, missed once and matched estimates once.
There are two different EPS estimates to keep in mind. The earnings calendar lists C$0.77, while earnings-trends data shows a consensus of C$0.55 from four analysts. The trends data also forecasts year-over-year declines of 0.8% in EPS and 7.1% in revenue. Investors should check which estimate the reported results are compared with. You can find more company information on the DRI Healthcare Trust stock page.
Recent earnings trend
DRI Healthcare Trust
DHT-UN.TO
DHT-UN.TO
DRI Healthcare Trust
WealthAwesomeMarket cap
$1.02B
Div. yield
2.32%
Div. / share
$0.42
52W high
$19.58
52W low
$14.61
1W change
+0.55%
Beta
0.62
Analyst Price Targets
Based on analyst covering DHT-UN · as of Nov 2, 2026
Wall Street analysts forecast DHT-UN stock price to rise 30.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$23.99
+30.9% Upside
Previously C$24.03 on Oct 30, 2026
Current Price
C$18.33
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on DHT-UN's historical volatility
30-Day Vol
18.8%
Annualized
90-Day Vol
24.7%
Annualized
Trend (90d)
+28.9%
Annualized drift
90d Mean
C$20.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$18.97 | C$17.78 – C$20.24 |
| 60 trading days | C$19.64 | C$17.92 – C$21.52 |
| 90 trading days | C$20.33 | C$18.17 – C$22.74 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 4 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-04 | — | 0.7700 | — |
| 2026-06-30 | 2026-08-07 | 0.5600 | 0.6000 | -6.7% |
| 2026-03-31 | 2026-05-14 | 0.6800 | 0.5500 | +23.6% |
| 2025-12-31 | 2026-03-03 | 0.7800 | 0.5200 | +50.0% |
| 2025-09-30 | 2025-11-05 | 0.5500 | 0.5500 | +0.0% |
| 2025-06-30 | 2025-08-13 | 0.5100 | 0.4800 | +6.3% |
Investor takeaway: DRI’s November 4 earnings report will show whether the company can maintain its income and cash-generation momentum as analysts expect lower EPS and revenue year over year. The EPS consensus has slipped from C$0.57 to C$0.55 over the past 30 days. Only four analysts contributed to that consensus, and the calendar lists a separate C$0.77 estimate. Treat them as different figures until their reporting basis is clear. DRI’s recent results don’t show a consistent pattern of beats: the company beat estimates twice, missed once and matched once.
C$0.55 EPS consensus, with a separate C$0.77 calendar estimate
Earnings-trends data puts EPS consensus at C$0.55, down from C$0.57 30 days ago, based on four analysts. The earnings calendar lists C$0.77. Revenue consensus is $45.3 million, based on seven analysts. Check the estimate basis when results come out rather than assuming the two EPS figures are comparable.
Bull case
DRI has beaten expectations in recent quarters, including by 23.64% in March and 50% in December. The company described its Q2 2026 results as records for quarterly income, cash receipts and adjusted EBITDA.
Before the upcoming report, DRI announced a purchase of royalty rights tied to tavapadon, which received FDA approval in September. The company also said it received about US$178 million after exercising its contractual put option on the EKTERLY royalty interest. These developments add context, but the available information doesn’t show how much they contributed to the September quarter.
Bear case
DRI missed EPS estimates in its latest reported quarter, and current forecasts point to lower EPS and revenue year over year. Analysts have also lowered the EPS consensus over the past month, with two downward revisions and one upward revision.
The supplied fundamentals show negative trailing EPS and profit margin, so quarterly EPS alone may not give a full picture of the company’s financial performance. The tavapadon royalty acquisition and EKTERLY proceeds are significant developments, but their timing and accounting treatment could make comparisons between quarters harder.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
